Mumbai: Shilpa Medicare’s biotech research arm Shilpa Biocare Pvt Ltd has announced a 30.4% equity stake acquisition in Spanish biotechnology firm Gate2Brain, S.L. as it looks to strengthen research in emerging oncology treatments. The deal worth about €7 million, is aimed at contributing to the ‘manufacturing and regulatory depth required to bring G2B-002 to first-in-human studies and extend its application to other molecules and therapy categories,’ the company said in a press release.

Gate2Brain is developing the G2B-002 anticancer agent aimed at treating lethal childhood intrinsic pontine glioma (DIPG) and pediatric glioblastoma (pGBM) brain cancers. Through its MiniAp4 peptide shuttle, Gate2Brain has demonstrated up to 100-fold greater brain drug transport than conventional methods. 

For Shilpa Medicare, this means an estimated $3.01 billion market opportunity with a CAGR of about 7.97%. Gate2Brain’s peptide shuttle platform is also expected to work across other rare pediatric cancers, further expanding its long-term commercial opportunities.

Shilpa Medicare has been on a roll lately, as the API maker reported strong revenue growth for FY26 and is now looking to reinforce its emphasis on building a portfolio of high-potential therapeutic assets that drive long-term value creation for shareholders and society.

“Gate2Brain’s blood-brain-barrier technology is among the most differentiated CNS-delivery platforms we have evaluated. Becoming a strategic shareholder allows Shilpa to participate in long-term value creation while contributing the manufacturing and regulatory depth required to bring G2B-002 to first-in-human studies and extend its application to other molecules and therapy categories.” Vishnukant Bhutada, Managing Director, Shilpa Medicare, said.

 

“This partnership gives G2B-002 a clear, de-risked path to the clinic and validates our peptide-shuttle platform with a top-tier oncology partner. Aligning Shilpa’s manufacturing and regulatory capabilities with our science is the right structure to deliver this program — and the next ones — to patients.” Meritxell Teixidó Turà, CEO, Gate2Brain added.

Abizar has been writing before AI started to take over your lives! His expertise lies in analysing diverse perspectives and simplifying them for laymen. Beyond writing, storytelling and editing, he enjoys running, learning and enjoying the outdoors.

HEgoogleNews